Intravenous formulation of N-hydroxy-N′-(4-n-butyl-2-methylphenyl) formamidine (HET0016) for inhibition of rat brain 20-hydroxyeicosatetraenoic acid formation

Drug Metabolism and Disposition

Volumn 36, Issue 11, 2008, Pages 2324-2330

  Mu, Ying ^a   Klamerus, Megan M ^a   Miller, Tricia M ^a   Rohan, Lisa C ^a,b   Graham, Steven H ^c,d   Poloyac, Samuel M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 20 HYDROXYICOSATETRAENOIC ACID; CYTOCHROME P450 ISOENZYME; FORMAMIDE DERIVATIVE; HET 0016; N HYDROXY N' (4 N BUTYL 2 METHYLPHENYL)FORMAMIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN MICROSOME; BRAIN PROTECTION; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG SOLUBILITY; ICOSANOID METABOLISM; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE;

AMIDINES; ANIMALS; BRAIN; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 ENZYME SYSTEM; HYDROXYEICOSATETRAENOIC ACIDS; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 54349105658     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023150     Document Type: Article

References (25)

1. Amaral SL, Maier KG, Schippers DN, Roman RJ, and Greene AS (2003) CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol 284:H1528-H1535.
2. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, et al. (2005) Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111:63-69.
3. Gould S and Scott RC (2005) 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 43:1451-1459.
4. Govindarajan R and Nagarsenker MS (2005) Formulation studies and in vivo evaluation of a flurbiprofen-hydroxypropyl beta-cyclodextrin system. Pharm Dev Technol 10:105-114.
5. Harder DR, Gebremedhin D, Narayanan J, Jefcoat C, Falck JR, Campbell WB, and Roman RJ (1994) Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol Heart Circ Physiol 266:H2098-H2107.
6. Jarho P, Urtti A, and Järvinen T (1995) Hydroxypropyl-beta- cyclodextrin increases the aqueous solubility and stability of pilocarpine prodrugs. Pharm Res 12:1371-1375.
7. Kalsotra A, Zhao J, Anakk S, Dash PK, and Strobel HW (2007) Brain trauma leads to enhanced lung inflammation and injury: evidence for role of P4504Fs in resolution. J Cereb Blood Flow Metab 27:963-974.
8. Lowry H, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
9. Luo G, Zeldin DC, Blaisdell JA, Hodgson E, and Goldstein JA (1998) Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch Biochem Biophys 357:45-57.
10. Mayer B, Lieb W, Götz A, König IR, Kauschen LF, Linsel-Nitschke P, Pomarino A, Holmer S, Hengstenberg C, Doering A, et al. (2006) Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 24:1965-1970.
11. Meyer RP, Gehlhaus M, Knoth R, and Volk B (2007) Expression and function of cytochrome P450 in brain drug metabolism. Curr Drug Metab 8:297-306.
12. Miyata N, Seki T, Tanaka Y, Omura T, Taniguchi K, Doi M, Bandou K, Kametani S, Sato M, Okuyama S, et al. (2005) Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4- morpholin-4-yl) phenyl-N′-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther 314:77-85.
13. Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M, Kametani S, Tomishima Y, Ueki T, et al. (2001) HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol 133:325-329.
14. Nakamura T, Sato M, Kakinuma H, Miyata N, Taniguchi K, Bando K, Koda A, and Kameo K (2003) Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors. J Med Chem 46:5416-5427.
15. Omura T, Tanaka Y, Miyata N, Koizumi C, Sakurai T, Fukasawa M, Hachiuma K, Minagawa T, Susumu T, Yoshida S, et al. (2006) Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke 37:1307-1313.
16. Pitha J, Irie T, Sklar PB, and Nye JS (1988) Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci 43:493-502.
17. Poloyac SM, Reynolds RB, Yonas H, and Kerr ME (2005) Identification and quantification of the hydroxyeicosatetraenoic acids, 20-HETE and 12-HETE, in the cerebrospinal fluid after subarachnoid hemorrhage. J Neurosci Methods 144:257-263.
18. Poloyac SM, Tortorici MA, Przychodzin DI, Reynolds RB, Xie W, Frye RF, and Zemaitis MA (2004) The effect of isoniazid on CYP2E1 and CYP4A mediated hydroxylation of arachidonic acid in the rat liver and kidney. Drug Metab Dispos 32:727-733.
19. Poloyac SM, Zhang Y, Bies RR, Kochanek PM, and Graham SH (2006) Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. J Cereb Blood Flow Metab 26:1551-1561.
20. Rockich KT and Blouin RA (1999) The effect of the acute phase response on the pharmacokinetics of chlorzoxazone and CYP2E1 in vitro activity in rats. Drug Metab Dispos 27:1074-1077.
21. Seki T, Wang MH, Miyata N, and Laniado-Schwartzman M (2005) Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N′-(4-butyl-2- methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol Pharm Bull 28:1651-1654.
22. Stec DE, Gannon KP, Beaird JS, and Drummond HA (2007) 20-Hydroxyeicosatetraenoic acid (20-HETE) stimulates migration of vascular smooth muscle cells. Cell Physiol Biochem 19:121-128.
23. Takeuchi K, Renic M, Bohman QC, Harder DR, Miyata N, and Roman RJ (2005) Reversal of delayed vasospasm by an inhibitor of the synthesis of 20-HETE. Am J Physiol Heart Circ Physiol 289:H2203-H2211.
24. Trapani G, Latrofa A, Franco M, Lopedota A, Sanna E, and Liso G (1998) Inclusion complexation of propofol with 2-hydroxypropyl-beta-cyclodextrin. Physicochemical, nuclear magnetic resonance spectroscopic studies, and anesthetic properties in rat. J Pharm Sci 87:514-518.
25. Zhang X, Zhang QY, Liu D, Su T, Weng Y, Ling G, Chen Y, Gu J, Schilling B, and Ding X (2005) Expression of cytochrome p450 and other biotransformation genes in fetal and adult human nasal mucosa. Drug Metab Dispos 33:1423-1428.